The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models

Joan Kyula, Victoria Roulstone, James C. Wright, Francesca Butera, Arnaud J. Legrand, Richard Elliott, Martin McLaughlin, Galabina Bozhanova, Dragomir B. Krastev, Stephen J. Pettitt, Tencho Tenev, Magnus T. Dillon, Shane Foo, Emmanuel C. Patin, Victoria A. Jennings, Charleen Chan Wah Hak, Elizabeth Appleton, Amarin Wongariyapak, Malin Pedersen, Antonio Rullan, Jyoti S. Choudhary, Chris Bakal, Pascal Meier, Christopher J. Lord, Alan Melcher, Kevin J. HarringtonNature Communications 2025 · DOI

Abstract

Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizers, we conducted a high-throughput screen of therapeutic agents and identified the PARP-1 inhibitor, talazoparib, as a top hit. Mechanistically, RT3D activates PARP-1 via RIG-I, leading to the PARylation of extrinsic apoptosis pathway components that act as a "brake" on cell death. Pharmacological inhibition of PARP-1 with talazoparib abrogates this brake, enhancing apoptosis and pro-inflammatory signaling. In vivo, this combination induces complete tumor control and long-term immune memory, protecting mice from subsequent tumor rechallenge.

Introduction

Oncolytic viruses (OVs) are designed to selectively infect and destroy cancer cells. While promising, their clinical efficacy as monotherapies is often limited by tumor resistance and rapid viral clearance. To overcome these barriers, researchers seek "sensitizers"—drugs that can amplify the viral effect. This study identifies talazoparib, a PARP inhibitor (PARPi), as a potent sensitizer for Reovirus type 3 Dearing (RT3D), revealing a novel non-canonical role for PARP-1 in viral-induced cell death.

Methods and Experimental Design

The researchers utilized an unbiased high-throughput screen of 80 therapeutic agents to identify sensitizers in melanoma cell lines. Following the identification of talazoparib, the team employed:

  • Proteomics: TMT-11plex mass spectrometry to map signaling pathways.
  • Genetic Validation: CRISPR-Cas9 to knockout PARP-1, confirming its role as the primary mediator.
  • Biochemical Assays: Immunoprecipitation and PARP-trap assays to observe the RIG-I/dsRNA/PARP-1 complex.
  • In Vivo Models: Syngeneic mouse models (4434 melanoma) were used to evaluate tumor control and immune memory.

Key Insights: A Non-Canonical Mechanism

The synergy between talazoparib and RT3D does not depend on the classic "synthetic lethality" associated with DNA repair defects (e.g., BRCA mutations). Instead, it involves a novel immune-signaling pathway:

  1. The Brake: RT3D infection triggers the RIG-I sensor, which recruits PARP-1. PARP-1 then PARylates the cell's death machinery (the DISC complex), preventing rapid apoptosis and allowing the tumor to survive.
  2. The Release: Talazoparib inhibits PARP-1 and "traps" it on the RIG-I/dsRNA complex. This prevents the inhibitory PARylation, flipping the switch from survival to pro-inflammatory cell death.
  3. Positive Feedback: This process activates IFN-β and TNF/TRAIL production, further amplifying the therapeutic effect.

Results

Potent In Vitro Synergy

Talazoparib demonstrated "supra-additive" cell killing across multiple melanoma and breast cancer cell lines. The effect was dose-dependent, with even low concentrations of talazoparib significantly lowering the threshold for viral-induced death.

Synergistic cell killing in MeWo cells across varying doses of talazoparib and RT3D.

Complete Tumor Control and Immune Memory

In immunocompetent mouse models, the combination of RT3D and talazoparib achieved a 100% cure rate (6/6 mice). Beyond initial clearance, the treatment acted as an in situ vaccine. Mice that were successfully cured rejected a second injection of the same tumor cells months later, indicating the development of robust, long-term adaptive immune memory.

Percent survival over time in mouse models showing complete protection with the RT3D and talazoparib combination.

Discussion and Future Directions

This study highlights a powerful new strategy for enhancing oncolytic virotherapy. By repurposing PARP inhibitors to target viral sensing pathways rather than DNA repair, the scope of PARPi therapy could be expanded to a broader range of cancers.

However, challenges remain for clinical translation. Optimal dosing schedules must be established to balance efficacy and toxicity. Furthermore, the observation that the treatment upregulates PD-L1 suggests that combining this regimen with immune checkpoint inhibitors (anti-PD-1/PD-L1) could further enhance its potency, particularly in "cold" or resistant tumors.

Summary updated

Abstract

Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizer, here we use a high-throughput screen of therapeutic agents and find a PARP-1 inhibitor, talazoparib, as a top hit. RT3D interacts with retinoic acid-induced gene-1 (RIG-I) and activates PARP-1, with consequent PARylation of components of the extrinsic apoptosis pathway. Pharmacological or genetic inhibition of PARP-1 abrogates this PARylation and enhances extrinsic apoptosis, NF-kB signalling and pro-inflammatory cell death. Interaction between PARP-1 and RIG-I induced by treating RT3D-infected cells with talazoparib activates downstream IFN-β and TNF/TRAIL production to amplify the therapeutic effect through positive feedback. Furthermore, the effect of RT3D-talazoparib combination is phenocopied by non-viral ds-RNA therapy and RIG-I agonism. In vivo, mouse tumour model results show that RT3D/talazoparib combination regimen induces complete control of inoculated tumour as well as protection from subsequent tumour rechallenge with the, with accompanied innate and adaptive immune activation.
BibTeX
@inproceedings{kyula2025parp,
  author = {Joan Kyula and Victoria Roulstone and James C. Wright and Francesca Butera and Arnaud J. Legrand and Richard Elliott and Martin McLaughlin and Galabina Bozhanova and Dragomir B. Krastev and Stephen J. Pettitt and Tencho Tenev and Magnus T. Dillon and Shane Foo and Emmanuel C. Patin and Victoria A. Jennings and Charleen Chan Wah Hak and Elizabeth Appleton and Amarin Wongariyapak and Malin Pedersen and Antonio Rullan and Jyoti S. Choudhary and Chris Bakal and Pascal Meier and Christopher J. Lord and Alan Melcher and Kevin J. Harrington},
  title = {{The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models}},
  booktitle = {Nature Communications},
  year = {2025},
  doi = {10.1038/s41467-025-61297-w},
}
Figure